These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 24912192)

  • 41. Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors.
    Stefanoli M; La Rosa S; Sahnane N; Romualdi C; Pastorino R; Marando A; Capella C; Sessa F; Furlan D
    Neuroendocrinology; 2014; 100(1):26-34. PubMed ID: 25011998
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
    Pea A; Hruban RH; Wood LD
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis.
    Pieterman CR; Conemans EB; Dreijerink KM; de Laat JM; Timmers HT; Vriens MR; Valk GD
    Endocr Relat Cancer; 2014 Jun; 21(3):R121-42. PubMed ID: 24389729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A systems biology approach to define mechanisms, phenotypes, and drivers in PanNETs with a personalized perspective.
    Werle SD; Ikonomi N; Lausser L; Kestler AMTU; Weidner FM; Schwab JD; Maier J; Buchholz M; Gress TM; Kestler AMR; Kestler HA
    NPJ Syst Biol Appl; 2023 Jun; 9(1):22. PubMed ID: 37270586
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
    Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
    Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification.
    Ishida H; Lam AK
    Crit Rev Oncol Hematol; 2022 Apr; 172():103648. PubMed ID: 35248713
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms.
    Krug S; Kühnemuth B; Griesmann H; Neesse A; Mühlberg L; Boch M; Kortenhaus J; Fendrich V; Wiese D; Sipos B; Friemel J; Gress TM; Michl P
    Endocr Relat Cancer; 2014; 21(6):879-90. PubMed ID: 25248790
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
    Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
    Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
    [No Abstract]   [Full Text] [Related]  

  • 49. Frequent deletion of chromosome 3 in malignant sporadic pancreatic endocrine tumors.
    Guo SS; Arora C; Shimoide AT; Sawicki MP
    Mol Cell Endocrinol; 2002 Apr; 190(1-2):109-14. PubMed ID: 11997184
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression.
    Di Domenico A; Pipinikas CP; Maire RS; Bräutigam K; Simillion C; Dettmer MS; Vassella E; Thirlwell C; Perren A; Marinoni I
    Commun Biol; 2020 Dec; 3(1):740. PubMed ID: 33288854
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Generation and characterization of CRISPR/Cas9-mediated MEN1 knockout BON1 cells: a human pancreatic neuroendocrine cell line.
    Monazzam A; Li SC; Wargelius H; Razmara M; Bajic D; Mi J; Bergquist J; Crona J; Skogseid B
    Sci Rep; 2020 Sep; 10(1):14572. PubMed ID: 32884006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors.
    Wu Y; Tedesco L; Lucia K; Schlitter AM; Garcia JM; Esposito I; Auernhammer CJ; Theodoropoulou M; Arzt E; Renner U; Stalla GK
    Oncotarget; 2016 Sep; 7(36):57878-57893. PubMed ID: 27506944
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome.
    D'Adda T; Keller G; Bordi C; Höfler H
    Lab Invest; 1999 Jun; 79(6):671-7. PubMed ID: 10378509
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Cell Death Inhibitor ARC Is Induced in a Tissue-Specific Manner by Deletion of the Tumor Suppressor Gene Men1, but Not Required for Tumor Development and Growth.
    McKimpson WM; Yuan Z; Zheng M; Crabtree JS; Libutti SK; Kitsis RN
    PLoS One; 2015; 10(12):e0145792. PubMed ID: 26709830
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas.
    Perren A; Anlauf M; Henopp T; Rudolph T; Schmitt A; Raffel A; Gimm O; Weihe E; Knoefel WT; Dralle H; Heitz PU; Komminoth P; Klöppel G
    J Clin Endocrinol Metab; 2007 Mar; 92(3):1118-28. PubMed ID: 17179192
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of p27
    Conemans EB; Raicu-Ionita GM; Pieterman CRC; Dreijerink KMA; Dekkers OM; Hermus AR; de Herder WW; Drent ML; van der Horst-Schrivers ANA; Havekes B; Bisschop PH; Offerhaus GJ; Borel Rinkes IHM; Valk GD; Timmers HTM; Vriens MR
    J Endocrinol Invest; 2018 Jun; 41(6):655-661. PubMed ID: 29134609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors.
    Wong C; Laddha SV; Tang L; Vosburgh E; Levine AJ; Normant E; Sandy P; Harris CR; Chan CS; Xu EY
    Cell Death Dis; 2014 Oct; 5(10):e1450. PubMed ID: 25299775
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The hereditary forms of pancreatic neuroendocrine tumors.
    DeLellis RA
    Adv Anat Pathol; 1999 May; 6(3):149-53. PubMed ID: 10342012
    [TBL] [Abstract][Full Text] [Related]  

  • 59. STK33 Promotes the Growth and Progression of Human Pancreatic Neuroendocrine Tumour via Activation of the PI3K/AKT/mTOR Pathway.
    Zhou B; Xiang J; Zhan C; Liu J; Yan S
    Neuroendocrinology; 2020; 110(3-4):307-320. PubMed ID: 31261148
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice.
    Fuentes ME; Lu X; Flores NM; Hausmann S; Mazur PK
    Sci Rep; 2024 Apr; 14(1):8510. PubMed ID: 38609433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.